European Committee for Medicinal Products for Human Use approves update to Gardasil® SmPC to include long-term protection data

Immunogenicity and effectiveness data from long-term follow-up of Gardasil® studies demonstrates sustained protection against HPV 6, 11, 16 and 18 disease September 12, 2014 Sanofi Pasteur MSD announced today that the Summary of Product characteristics (SmPC) of Gardasil has been updated to include new data related to long-term protection. (1) The duration of protection of Gardasil is being monitored through different …

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus

The HPV Cancer Vaccine: Two Doses May Be Enough

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the vaccine to boost adherence rates. …

Young HIV Positive People Respond Well to HPV Vaccine

Young HIV Positive People Respond Well to HPV Vaccine

The study, Presented at the International AIDS Conference in Melbourne Last Week, Showed that the HPV Vaccine Works Just as Well for HIV-Positive Patients as it Does for HIV-Negative People Human Papillomavirus, the most common sexually transmitted infection, occurs in a variety of strains that vary in severity. People will typically become infected with HPV after they have become sexually …

Top 10 Vaccines in 2013

  #10 – Pneumovax Pneumococcal infection 2013 – $653 million 2012 – $580 million Marketed by Merck and Sanofi Pasteur MSD #9 – RotaTeq Rotaviral gastroenteritis 2013 – $691 million 2012 – $648 million Marketed by Merck and Sanofi Pasteur MSD #8 – Zostavax Herpes Zoster (Shingles) 2013 – $826 million 2012 – $ N/A Marketed by Merck and Sanofi Pasteur MSD #7 – Hepatitis vaccine franchise Hepatitis A, Hepatitis B 2013 – $984 million 2012 …

Gardasil Approved in Europe for the Prevention of Anal Cancer

The European Commission granted a new indication for Gardasil®, for the prevention of anal cancer and anal precancerous lesions caused by specific oncogenic HPV types in both females and males June 18, 2014 Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for the use of Gardasil for the prevention of anal precancerous lesions and anal …

Gardasil® 2-dose schedule approved in the European Union for children aged from 9 to 13 years

Alternative regimen for quadrivalent HPV vaccine now available for 9-13 year olds April 3, 2014 Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for a 2-dose schedule at 0 and 6 months in children aged from 9 to 13 years for its quadrivalent Human Papillomavirus (HPV) vaccine. Gardasil® is the only quadrivalent HPV vaccine and …